What are Glaukos's Business Segments?
Glaukos Corporation is a medical technology company that develops and commercializes innovative surgical devices and sustained pharmaceutical therapies designed to treat glaucoma, corneal disorders, and retinal diseases. The company is focused on advancing ophthalmic care by developing breakthrough solutions that enhance patient outcomes, reduce healthcare costs, and minimize complications associated with traditional surgical procedures.
Segments:
Glaukos Corporation operates in two segments - Glaucoma and Corneal Health.
1. Glaucoma Segment: This segment is dedicated to the research, development, and commercialization of novel medical devices that help prevent and treat glaucoma. Glaukos' flagship product, iStent, is the first micro-invasive glaucoma surgery device that is FDA-approved for the primary treatment of mild-to-moderate open-angle glaucoma. The iStent enables surgeons to reduce intraocular pressure (IOP) and improve the visual function of patients by enhancing aqueous drainage from the eye. The company also manufactures iStent Inject, a second generation micro-invasive glaucoma surgery device that provides predictable and sustained reduction in IOP by creating a bypass between the anterior chamber and Schlemm's canal. Other products offered in this segment include iStent SA, iStent Supra, and iDoseTR, all of which facilitate sustained-release drug delivery to the eye.
2. Corneal Health Segment: This segment is focused on developing innovative solutions to treat corneal diseases and disorders such as keratoconus, which involves a restructuring of the cornea leading to distorted vision, and Fuchs Endothelial Corneal Dystrophy (FECD), which damages the endothelial layer of the cornea causing blisters and clouding. The company offers the following products in this segment - the iLink MicroShunt, which is a minimally-invasive surgical solution designed to treat moderate-to-severe glaucoma cases in combination with cataract surgery, the iDose Travoprost, a sustained-release drug delivery system that reduces IOP by delivering Travoprost directly to the affected eye, and the iStent infinite, a comprehensive glaucoma management system that allows the surgeon to implant iStents into multiple areas of the eye.
Products:
iStent: iStent is a device implanted during cataract surgery that lowers pressure in the eye, reducing the need for glaucoma medication.
iStent inject: iStent inject is a second-generation device implanted during cataract surgery to provide sustainable IOP reduction.
iStent Supra: The iStent Supra device is inserted into the suprachoroidal space, where it facilitates outflow of aqueous humor from the anterior chamber into the suprachoroidal space.
iDose: The iDose device is a minimally invasive, implantable system designed to release sustained amounts of medication to the eye over time.
iLink microshunt: The iLink microshunt is a flexible, biocompatible tube that shunts aqueous humor from the anterior chamber into the subconjunctival space.
iStent infinite: The iStent infinite system is a comprehensive management solution that allows for implantation of iStents in multiple areas of the eye.
Services:
Glaukos has developed a range of surgical and therapeutic services designed to meet the needs of ophthalmic professionals and patients. These include:
e Comprehensive patient evaluation services for diagnosing and treating glaucoma and corneal disorders e Patient education and support programs e Ongoing device monitoring and follow-up care e Continuing education programs for ophthalmic professionals e Cloud-based data platforms and predictive analytics to improve patient care and outcomes
In conclusion, Glaukos Corporation is a leading innovator in the field of ophthalmic surgery and therapy, offering a comprehensive range of products and services designed to meet the needs of patients and healthcare providers. Its devices and therapies aim to reduce healthcare costs and minimize complications associated with traditional surgical procedures, ultimately advancing ophthalmic care and improving patient outcomes.
|